At what serum potassium level should an angiotensin‑receptor blocker be discontinued?

At What Potassium Level Should ARBs Be Stopped?

ARBs should be discontinued or dose-reduced when serum potassium exceeds 6.5 mEq/L, according to the European Society of Cardiology guidelines. 1

Guideline-Based Thresholds for ARB Management

The approach to ARB continuation versus discontinuation varies by potassium level and clinical context:

Potassium 5.0-5.5 mEq/L (Mild Hyperkalemia)

• ARBs are typically NOT stopped at this level 1
• The American College of Cardiology/American Heart Association recommends using ARBs with caution but continuing therapy 1
• If ARB therapy is stopped for other reasons, reinitiate once potassium decreases to <5.0 mEq/L or returns to the patient's usual range (whichever is higher) 1

Potassium 5.6-5.9 mEq/L (Moderate Hyperkalemia)

• Continue ARB therapy while addressing the underlying cause 1
• Initiate potassium-lowering therapy (loop diuretics, newer potassium binders like patiromer or sodium zirconium cyclosilicate) 1
• Reintroduce ARBs one at a time with close monitoring if temporarily discontinued 1

Potassium >6.0-6.5 mEq/L (Severe Hyperkalemia)

• Discontinue ARB therapy according to the National Institute for Health and Care Excellence guidelines for patients with chronic kidney disease 1
• The European Society of Cardiology recommends discontinuation or dose reduction when potassium exceeds 6.5 mEq/L 1
• Potassium-lowering therapy should be started as soon as potassium exceeds 5.0 mEq/L 1

Critical Clinical Context

When ARBs Should Be Continued Despite Elevated Potassium

The mortality and morbidity benefits of ARBs often outweigh hyperkalemia risks in the 5.0-6.5 mEq/L range. The key is to use potassium-lowering strategies rather than reflexively stopping ARBs 2, 1:

• If patients are on maximum-tolerated guideline-recommended ARB doses, initiate potassium binders rather than stopping the ARB 1
• Clinical trials (RALES, EMPHASIS-HF) demonstrated that cardiovascular benefits persisted even with modest potassium elevations 2
• Up to one-third of heart failure patients develop potassium >5.0 mEq/L on renin-angiotensin-aldosterone system inhibitors, yet outcomes remain superior with continued therapy 2

Alternative Threshold from Research Evidence

Older research suggests ARB discontinuation when potassium reaches ≥5.6 mmol/L 3, 4, 5, but this threshold is more conservative than current guideline recommendations and should be applied cautiously given the proven mortality benefits of ARB therapy.

Common Pitfalls to Avoid

Premature Discontinuation

• Do not stop ARBs at potassium levels of 5.0-5.5 mEq/L without first attempting potassium-lowering interventions 1
• Discontinuing ARBs leads to adverse cardiorenal outcomes and increased mortality in heart failure and chronic kidney disease patients 2, 1
• Less than one-third of patients achieve guideline-recommended target ARB doses, with hyperkalemia cited as a reason in 35% of cases—often inappropriately 2

Inadequate Monitoring

• Check potassium and kidney function within 1 week of ARB initiation or dose escalation 1
• Recheck within 2-4 weeks, as potassium typically stabilizes by this time 4
• Quality improvement programs are needed as potassium levels are frequently under-monitored in real-world practice 2

Failure to Use Potassium-Lowering Strategies

Before stopping ARBs, optimize the following 2, 1:

• Loop diuretics to increase renal potassium excretion
• Dietary potassium restriction
• Newer potassium binders (patiromer, sodium zirconium cyclosilicate) which allow ARB continuation
• Correction of metabolic acidosis with sodium bicarbonate

Missing Reversible Causes

Evaluate for concurrent conditions that elevate potassium 1:

• Volume depletion from diuretics or gastroenteritis
• NSAID use
• Potassium supplements or high-potassium diet
• Other medications (potassium-sparing diuretics, trimethoprim)

Practical Algorithm

1. Potassium <5.0 mEq/L: Continue ARB, monitor regularly 1
2. Potassium 5.0-5.5 mEq/L: Continue ARB, add potassium-lowering therapy, address reversible causes 1
3. Potassium 5.6-6.5 mEq/L: Continue ARB if on target dose, initiate aggressive potassium-lowering therapy, consider temporary dose reduction 1
4. Potassium >6.5 mEq/L: Discontinue or reduce ARB dose, initiate urgent potassium-lowering therapy 1